Acrux Limited Overview
Acrux Limited is a Melbourne-based micro-capitalisation specialty pharmaceutical company with a 25-year heritage in transdermal and topical drug delivery, best known for inventing the "patchless patch" metered-dose transdermal spray technology behind Evamist/Lenzetto (estradiol) and Axiron (male testosterone), the latter licensed to Eli Lilly in 2010 in a deal valued at up to US$335 million. After Axiron's commercial collapse in 2017, Acrux spent 2017–2025 building a portfolio of US generic topical products under ANDAs, achieving multiple FDA approvals but only modest licensing income. In FY2026, under new CEO John Warmbrunn, the company ceased its generic pipeline, monetised legacy assets and repositioned around a single high-value asset: a Female Testosterone Metered Dose Transdermal System for Hypoactive Sexual Desire Disorder (HSDD), a market without an FDA-approved testosterone product for women. Acrux now seeks a co-development partner to fund Phase III, while living off a small profit-share and milestone income base.
Company's own description. In its FY2026 Annual Report, Acrux describes itself as a specialty pharma company with a successful track record of developing and commercialising topically applied pharmaceutical products, drawing on 25 years of experience and having marketed products through licensees worldwide with emphasis on the United States. Crucially, the FY2026 Appendix 4E and Directors' Report add that during FY26 there was "a shift of emphasis to the development of testosterone to be applied transdermally in a metered dose suitable for women and cessation of progression of the topical generic pipeline." The Annual Report's cover theme is "Female Testosterone MDTS — the catalyst to accelerate Acrux's commercial success," and management states that Acrux will pursue Female Testosterone "through licensing its intellectual property using a co-development business model."
What the company does. Acrux formulates, develops and obtains regulatory approval for topically and transdermally applied medicines, and then out-licenses commercialisation to in-market partners. It does not manufacture at commercial scale (it uses contract manufacturing organisations; eight CMOs were contracted as at FY24) and it does not operate its own sales force. Its West Melbourne site (1,735 m²) houses laboratories, offices and warehousing, and is licensed by the TGA to manufacture certain products to clinical-trial stage.
Business model and revenue model. Acrux is a licensing and royalty business. Its revenue model has four strands, all disclosed in FY2026 Note 4: (1) profit share and royalty income from US generic products marketed by licensees (TruPharma, Padagis) — AUD 2,948k in FY26, including AUD 829k (US$550k) from the divestment of the Prilocaine/Lidocaine cream ANDA; (2) licensing and milestone income — AUD 1,350k in FY26 from Gedeon Richter's Australian Lenzetto licence, with up to a further AUD 4,050k contingent on TGA approval and sales; (3) fee-for-service technical work for third parties — AUD 346k in FY26; and (4) "other revenue," overwhelmingly the Australian Government R&D Tax Incentive (RDTI) refundable offset — AUD 1,937k in FY26 — plus small interest income. There is no product sales revenue in the conventional sense, no subscription revenue and no service-contract backlog. On a FY2026 basis the mix was approximately 45% profit share/royalty, 20% licensing milestone, 5% fee-for-service and 30% government grant (RDTI) and interest.
Value-chain position. Acrux sits at the upstream end of the pharmaceutical value chain: formulation science, analytical and CMC development, bioequivalence and clinical-study design, regulatory dossier preparation (ANDA, NDA/505(b)(2), TGA), device know-how (metered-dose applicators) and technology transfer. Downstream manufacturing, distribution, payer contracting and promotion are performed by partners.
Customer types. Acrux's direct customers are pharmaceutical companies: US generic marketers (TruPharma for nitroglycerin and dapsone; Padagis for Evamist and, until December 2025, the prilocaine/lidocaine cream), a European branded women's-health company (Gedeon Richter Plc for Lenzetto in 40+ countries, and from May 2026 Australia), a Gulf distributor (Servacure Trading W.L.L. for Dapsone 5% in Saudi Arabia, July 2025), and fee-for-service clients. Prospective co-development partners for Female Testosterone are, per the FY26 Chair/CEO report, undertaking due diligence in Acrux's data room; none has been named.
End-markets. Historically the US generic dermatology/topical prescription market (acne, anal-fissure pain, topical anaesthesia, onychomycosis) and the global menopause hormone therapy (MHT) market. Prospectively, female sexual dysfunction (HSDD) and broader women's health (premature menopause, post-cancer sexual dysfunction, potentially cognitive symptoms).
Independent characterisation. Acrux is best understood today as a single-asset, partnering-dependent women's-health development company with a small, declining-risk royalty "annuity" attached. Its balance sheet is thin (AUD 1.7 million cash and AUD 1.5 million equity at 30 June 2026) and its FY2026 near-breakeven result (net loss AUD 604k) was enabled by non-recurring items (a AUD 1.35 million signing milestone and AUD 829k ANDA-divestment proceeds). The strategic pivot is rational given the commoditisation of US topical generics that management itself cites, but it transforms the investment case from incremental ANDA execution into a binary bet on securing a well-funded partner for a Phase III programme in an indication where several prior testosterone-for-women efforts (P&G's Intrinsa patch in Europe, BioSante's LibiGel) have failed commercially or clinically. Acrux's genuine differentiators are its heritage IP and know-how in metered-dose transdermal sprays, a completed Phase II dataset (the 90 µL dose met its primary endpoint on satisfying sexual events), existing FDA and TGA regulatory dialogue, and a long-standing relationship with Gedeon Richter, which already markets an Acrux spray in over 40 countries.
Strategy
Stated strategy (FY26 Annual Report themes). The FY26 Annual Report frames the year as one in which Acrux "transformed its business by monetising existing assets and established a core income stream from its portfolio of topical generic products," creating the foundation to pursue "a potentially significant new blockbuster opportunity" in Female Testosterone MDTS. The strategy rests on three stated pillars: (1) a changing regulatory and clinical environment for hormone replacement therapy (management cites growing regulatory and medical recognition, and recent changes to US hormone-therapy labelling); (2) leveraging Acrux's proven technology and know-how, including completed Phase I/II studies, to accelerate a differentiated product; and (3) addressing a substantial unmet need — approximately 4.9 million US menopausal women with HSDD, roughly 10% of adult women affected, and no FDA-approved testosterone product for women. The commercial model is co-development: Acrux contributes formulation, device, technical-transfer and regulatory capabilities, while a partner contributes clinical, financial, manufacturing and commercial resources.
This represents a decisive break from the strategy that prevailed from Q4 2017 to FY2025, whose three priorities (per the FY24 Annual Report) were revenue realisation, operational effectiveness and optimal portfolio management of US generic topicals.
ESG commitments. Acrux's ESG framework comprises environmental, social and governance tenets centred on waste and energy minimisation at its leased site; no quantified emissions targets have been set.
Medium-term financial targets and guidance. Acrux provides no quantitative revenue, earnings or cash-flow guidance and no medium-term financial targets. The only forward-looking financial statements are (a) up to AUD 4.05m of further Lenzetto Australia milestones expected from FY27, contingent on TGA approval and cumulative-sales triggers, payable within two years of launch; (b) expected FY26 RDTI of AUD 1.977m (of which AUD 0.95m already advanced); and (c) expected FY27 cost savings, unquantified. The company's own market-sizing — a US and EU HSDD market potential of US$21.3 billion per year and ~120 million women globally estimated to have HSDD by 2030 — is explicitly labelled by management as derived, illustrative and not sourced from any single market report, and should not be treated as a revenue target.
Products & Services
Acrux's portfolio is organised below into (A) the development asset now driving strategy, (B) on-market approved products generating income, (C) approved-but-not-launched or divested products, (D) discontinued pipeline, (E) legacy proprietary products, and (F) services and platform technology.
A. Development asset (strategic priority)
| Product | Description and capabilities | Target customer | Status (latest) | Pricing model | Source |
|---|---|---|---|---|---|
| Female Testosterone MDTS (testosterone metered-dose transdermal system for women) | Controlled-dose testosterone delivered through the skin of the abdomen via Acrux's proprietary applicator and "patchless patch" spray technology; designed for simple, accurate, flexible dosing and reduced risk of incidental transfer; selected dose 90 µL | Pre- and post-menopausal women with HSDD; potential expansion to premature menopause, post-cancer sexual dysfunction, IVF/ovarian priming and cognitive decline (exploratory) | Phase I and Phase II completed (Phase II: increased satisfactory sexual events across all testosterone arms vs placebo; 90 µL dose statistically significant on primary endpoint). FDA pre-IND feedback sought July 2026 for Phase III and a potential 505(b)(2) pathway; TGA meeting December 2025 indicated a literature-based submission may be acceptable subject to bridging and device work. Not registered for any indication | Company illustrative assumption of US$300 per month treatment cost; out-licensing/co-development model; no partner terms disclosed | FY26 Annual Report; ASX 28 Apr 2026; ASX 6 Aug 2026 |
B. On-market products generating income (US unless stated)
| Product | Reference brand / indication | Licensee / marketer | Launch | Addressable market (IQVIA, 12 months to June 2024) | Economics to Acrux | Source |
|---|---|---|---|---|---|---|
| Nitroglycerin Ointment 0.4% | Generic of AbbVie's Rectiv; pain associated with chronic anal fissure | TruPharma | December 2024 | US$22.7m | Profit share | FY24 and FY26 Annual Reports |
| Dapsone Gel 5% | Generic of Aczone 5%; acne vulgaris | TruPharma (US); Servacure Trading W.L.L. (Saudi Arabia, licence July 2025) | April 2024 (US) | US$15.8m | Profit share (US); Saudi terms not disclosed | FY24 and FY26 Annual Reports |
| Dapsone Gel 7.5% | Generic of Aczone 7.5%; acne vulgaris | TruPharma | May 2025 (FDA approval August 2024) | US$37.4m | Profit share | FY24 and FY26 Annual Reports |
| Estradiol Spray (Evamist) | Menopause hormone therapy — symptoms of oestrogen deficiency post-menopause | Padagis (US) | Originally approved 2007 | — | Royalty/profit share (terms not disclosed) | FY24 and FY26 Annual Reports |
| Lenzetto (estradiol transdermal spray) | MHT; ex-US brand name of Acrux's estradiol spray | Gedeon Richter Plc, more than 40 countries; Australia added May 2026 (pending TGA registration) | Marketed for multiple years ex-US; Australian launch pending | Gedeon Richter sales of approx. EUR 50m in 2025 | Ex-Australia royalties sold to Richter for EUR 4.1m (January 2023); Australia: up to AUD 5.4m in milestones (AUD 1.35m received June 2026) | ASX 28 May 2026; FY24 Annual Report |
C. Approved but not marketed, or divested
| Product | Indication | Status | Source |
|---|---|---|---|
| Efinaconazole 10% Topical Solution (generic Jublia) | Onychomycosis (toenail fungus) | FDA-approved; launch timing governed by a Paragraph IV patent litigation settlement agreement; settlement date and entry date not publicly disclosed in reviewed filings | FY24 Annual Report |
| Prilocaine 2.5% and Lidocaine 2.5% Cream | Topical anaesthetic (generic EMLA); addressable market US$26.8m (IQVIA, June 2024) | Launched by Padagis December 2022; ANDA divested December 2025 for US$0.55m as a "low performing" product | FY24 and FY26 Annual Reports |
| Testosterone Topical Solution (generic Axiron) | Male hypogonadism | ANDA divested in the June quarter 2024 due to a rapidly declining, low-priced market | FY24 Annual Report |
D. Discontinued or status-uncertain pipeline
| Product | Indication | Last disclosed status | Source |
|---|---|---|---|
| Acyclovir 5% Cream | Cold sores | Under FDA review at August 2024; post-FY24 status not disclosed in the FY26 Annual Report (which lists four FDA-approved income-generating products and states the generic pipeline was ceased) — not publicly disclosed | FY24 and FY26 Annual Reports |
| Undisclosed early-stage generic projects | Topical, otic and ophthalmic generics | FY24: 15-product portfolio, 7 in development; FY26: "ongoing development work on the Company's pipeline of topical generic products was ceased" | FY24 and FY26 Annual Reports |
E. Legacy proprietary products (historical)
| Product | Description | Status | Source |
|---|---|---|---|
| Axiron (testosterone 2% solution, underarm metered-dose applicator) | Male testosterone replacement; licensed worldwide to Eli Lilly (2010); FDA-approved 2010; PBS-listed March 2013 | Agreement terminated September 2017; withdrawn from the US market | SmartCompany (2010); LabOnline (2013); Biotech Daily (2017) |
| Ellavie | Name used outside the US for the estradiol spray in some territories (circa 2010) | Superseded by Lenzetto branding with Gedeon Richter | Monash University (2010); GEN (2010) |
| Historical pipeline (Fentanyl UDTS, Oxybutynin MDTS, Nestorone contraceptive spray with the Population Council) | Early transdermal programmes circa 2004–2005 | Not progressed; current status not publicly disclosed | LabOnline (2005) |
F. Services and platform technology
Acrux offers fee-for-service technical development (formulation, analytical development, CMC, bioequivalence support) "as and when resources are available," generating AUD 346k in FY26 (FY25: nil). Its core platform is the Metered Dose Transdermal System (MDTS) or "patchless patch," a fast-drying volatile/non-volatile spray system that forms a reservoir in the skin; this underpinned Evamist/Lenzetto, Axiron and now Female Testosterone. Pricing for fee-for-service work is project-based with upfront deposits recognised as unearned revenue (AUD 72k at 30 June 2026).
Financial Narrative
Basis of preparation. Figures are from audited consolidated statements in the FY24 and FY26 Annual Reports (covering FY23–FY26) and the five-year KPI tables in those reports (covering FY22). All figures in AUD thousands unless noted. EBIT and EBITDA are computed as loss before tax plus interest expense (and plus depreciation and amortisation for EBITDA); Acrux does not report these measures.
Income statement
Notes and discrepancies: (1) FY23 interest expense uses cash finance costs (AUD 201k) as no separate P&L line was presented; FY24 likewise uses cash finance costs (AUD 179k). (2) FY23 total operating expenses of AUD 11,582k in the income statement exclude COGS of AUD 558k; the table adds COGS for comparability. (3) The FY26 KPI table in the Remuneration Report shows FY26 basic EPS of –0.16 cents, whereas the audited income statement and Note 8 show –0.14 cents; the audited figure is used. (4) FY22 net loss is from the FY22 Appendix 4E (AUD 9,834k, down 22% on FY21).
Margins and growth (computed)
Revenue CAGR (computed): FY2022–FY2026 four-year CAGR of total revenue = (6,596 / 5,103)^(1/4) – 1 ≈ 6.6%. Management's FY24 report cited a five-year CAGR of 52% for client-derived revenue and 9% for total revenue (FY19–FY24), but those figures include the AUD 3,957k of profitless API pass-through in FY24.
Commentary. The five-year income statement is dominated by one-offs rather than organic growth. FY23's AUD 11.9m revenue was inflated by the AUD 6.3m Lenzetto royalty monetisation, which converted a perpetual royalty stream into a one-time cash receipt and was accompanied by a AUD 321k impairment of the estradiol intangible. FY24's AUD 8.1m included AUD 4.0m of zero-margin API pass-through, which explains the collapse in gross margin to 51%. FY25 was the trough: revenue fell 44% to AUD 4.5m, external R&D remained elevated at AUD 2.3m, and the net loss of AUD 5.9m was the largest since FY22. FY26 is the inflection, but a qualified one: revenue rose 46% and the loss narrowed 90% to AUD 0.6m, driven by (a) a full year of Nitroglycerin and Dapsone 7.5% profit share, (b) the AUD 1.35m Gedeon Richter signing milestone, (c) AUD 0.83m from the Prilocaine/Lidocaine divestment, and (d) a 55% cut in external R&D (AUD 2,308k to AUD 1,041k) and a 17% cut in employee costs (AUD 5,093k to AUD 4,234k) as the generic pipeline was shut down. Excluding the two non-recurring items (AUD 2.18m), FY26 loss before tax would have been approximately AUD 2.65m. The fall in RDTI income (AUD 3,298k to AUD 1,937k) is a direct consequence of reduced eligible R&D spend and will persist unless Phase III spending ramps up.
Balance sheet
FY2022 cash is the opening cash balance of FY2023 per the FY24 cash-flow statement; FY2022 equity and accumulated losses are the 1 July 2022 opening balances per the FY24 statement of changes in equity.
Commentary. The balance sheet has contracted from AUD 13.3m total assets (FY23) to AUD 5.8m (FY26), and equity from AUD 8.7m to AUD 1.5m despite AUD 4.3m of equity raised across FY25–FY26. Intangibles have been nil since the January 2023 estradiol impairment, so book value is essentially cash, the RDTI receivable and the lease right-of-use asset. The only borrowing is the Radium Capital RDTI advance (AUD 950k at 16% p.a.), secured against the FY26 RDTI receivable of approximately AUD 1.98m and repayable when the ATO pays (expected around the December 2026 quarter). The PDF structure prohibits medium- or long-term debt, so the company cannot lever its balance sheet even if lenders were willing. Note the Appendix 4E reports net tangible assets per share of 0.3 cents in both FY25 and FY26.
Cash flow
Commentary. FY26 delivered the first positive operating cash flow (AUD 1.02m) since FY23, the product of a near-tenfold increase in receipts from product agreements (AUD 521k to AUD 4,969k) and AUD 2.0m lower payments. The 31 July 2026 Appendix 4C described FY26 customer receipts as up 960%, with AUD 5.002m received; the audited cash-flow statement shows AUD 4.969m versus AUD 0.521m (+854%) — a discrepancy of AUD 33k in the FY26 figure and in the growth percentage, likely reflecting classification differences between the 4C and the audited statements. FY26 cash also benefited from a timing effect: the AUD 3.05m FY25 RDTI rebate was received in September 2025, while the FY26 rebate (approximately AUD 1.98m) falls into FY27. Management stated in the 4C that it had approximately nine quarters of funding, while the audited liquidity note states funding for at least 15 months from balance date "together with the initiatives outlined" — the two are not inconsistent but the 4C figure relies on the standard Appendix 4C methodology, which ignores planned Phase III commitments.
Ratios (computed from filed figures)
ROIC invested capital = equity + borrowings + lease liabilities – cash (FY26: AUD 2,280k). Net debt/EBITDA is not meaningful where EBITDA is negative (FY24, FY25; cells left blank). DSO uses receivables from contracts with customers divided by revenue from product agreements × 365; the FY25 figure is distorted by year-end timing of TruPharma receivables. The cash conversion cycle is not meaningful because Acrux holds no inventory and has no trade-payable cycle linked to sales; it is therefore not reported.
Ratio commentary. Every profitability ratio is negative over the period, and returns are essentially meaningless on a AUD 1–3m equity base. The most relevant metrics for this company are liquidity and dilution rather than return on capital: the current ratio has recovered to 1.37x, but the business remains dependent on RDTI pre-funding at 16% interest and on equity issued at sub-one-cent prices. Shares on issue have grown 83% between FY22 (285.4m) and FY26 (522.8m), and by roughly 106% to approximately 588.5m after the July 2026 Tranche 2 issue.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue stream (AUD K)
| Revenue stream (AUD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Profit share and royalty income (AUD K) | — | 1,534 | 1,134 | 1,190 | 2,948 |
API pass-through sales (AUD K) | — | 558 | 3,957 | 0 | 0 |
Lenzetto royalty monetisation (AUD K) | — | 6,337 | 0 | 0 | 0 |
Licensing / milestone income (AUD K) | — | 0 | 0 | 0 | 1,350 |
Fee for service income (AUD K) | — | 0 | 0 | 0 | 346 |
RDTI grant revenue (AUD K) | — | 3,377 | 2,873 | 3,298 | 1,937 |
Interest (AUD K) | — | 122 | 134 | 40 | 15 |
Total revenue (AUD K) | 5,103 | 11,928 | 8,098 | 4,528 | 6,596 |
Revenue by Segment and Segment Margins & Growth (%)
| Segment metric (single segment, AUD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Segment revenue (AUD K) | 5,103 | 11,928 | 8,098 | 4,528 | 6,596 |
Segment result = loss before tax (AUD K) | -9,582 | -212 | -5,568 | -5,937 | -469 |
Segment pre-tax margin (%, computed) | -187.8 | -1.8 | -68.8 | -131.1 | -7.1 |
Revenue YoY growth (%, computed) | — | 133.7 | -32.1 | -44.1 | 45.7 |
Contribution to total revenue (%) | 100 | 100 | 100 | 100 | 100 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total revenue (AUD K) | 5,103 | 11,928 | 8,098 | 4,528 | 6,596 |
Revenue from product agreements (AUD K) | — | 8,429 | 5,091 | 1,190 | 4,644 |
Other revenue incl. RDTI and interest (AUD K) | — | 3,499 | 3,007 | 3,338 | 1,952 |
Cost of goods sold (AUD K) | — | 558 | 3,957 | 0 | 0 |
Gross profit (AUD K, computed) | — | 11,370 | 4,141 | 4,528 | 6,596 |
Employee benefits expense (AUD K) | — | 4,960 | 4,915 | 5,093 | 4,234 |
External R&D expense (AUD K) | — | 3,812 | 2,418 | 2,308 | 1,041 |
Depreciation and amortisation (AUD K) | — | 595 | 510 | 467 | 438 |
Impairment (AUD K) | — | 321 | 0 | 0 | 0 |
Total operating expenses incl. COGS (AUD K) | — | 12,140 | 9,709 | 10,464 | 7,065 |
Interest expense (AUD K) | — | 201 | 179 | 303 | 282 |
EBIT (AUD K, computed) | — | -11 | -5,389 | -5,634 | -187 |
EBITDA (AUD K, computed) | — | 584 | -4,879 | -5,167 | 251 |
Loss before tax (AUD K) | -9,582 | -212 | -5,568 | -5,937 | -469 |
Income tax expense (AUD K) | — | 552 | 232 | 8 | 135 |
Net loss (AUD K) | -9,834 | -764 | -5,800 | -5,945 | -604 |
Basic EPS (AUD cents) | -3.46 | -0.27 | -2.00 | -1.69 | -0.14 |
Diluted EPS (AUD cents) | -3.46 | -0.27 | -2.00 | -1.69 | -0.14 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Weighted average shares (millions) | — | 286.46 | 289.50 | 352.16 | 422.85 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | — | 95.3 | 51.1 | 100.0 | 100.0 |
EBIT (operating) margin (%) | — | -0.1 | -66.5 | -124.4 | -2.8 |
EBITDA margin (%) | — | 4.9 | -60.2 | -114.1 | 3.8 |
Pre-tax margin (%) | -187.8 | -1.8 | -68.8 | -131.1 | -7.1 |
Net margin (%) | -192.7 | -6.4 | -71.6 | -131.3 | -9.2 |
Revenue growth YoY (%) | — | 133.7 | -32.1 | -44.1 | 45.7 |
Balance Sheet and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD K) | — | 13,285 | 8,963 | 7,225 | 5,835 |
Cash and cash equivalents (AUD K) | 5,831 | 6,232 | 2,945 | 863 | 1,705 |
Receivables incl. RDTI (AUD K) | — | 3,306 | 2,889 | 3,791 | 2,370 |
Total current assets (AUD K) | — | 9,891 | 5,981 | 4,803 | 4,108 |
Total current liabilities (AUD K) | — | 2,390 | 3,722 | 4,480 | 2,996 |
Short-term borrowings — RDTI advance (AUD K) | — | 0 | 1,487 | 1,727 | 950 |
Long-term borrowings (AUD K) | — | 0 | 0 | 0 | 0 |
Lease liabilities total (AUD K) | — | 2,353 | 2,217 | 1,908 | 1,568 |
Net debt excl. leases (AUD K, computed) | — | -6,232 | -1,458 | 864 | -755 |
Net debt incl. leases (AUD K, computed) | — | -3,879 | 759 | 2,772 | 813 |
Total liabilities (AUD K) | — | 4,589 | 5,687 | 6,202 | 4,368 |
Total equity (AUD K) | 9,090 | 8,696 | 3,276 | 1,023 | 1,467 |
Goodwill and intangibles (AUD K) | — | 0 | 0 | 0 | 0 |
Working capital (AUD K, computed) | — | 7,501 | 2,259 | 323 | 1,112 |
Accumulated losses (AUD K) | -113,723 | -114,487 | -120,287 | -126,232 | -126,836 |
Shares on issue (millions) | 285.36 | 288.18 | 290.72 | 407.76 | 522.78 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from product agreements (AUD K) | — | 8,534 | 5,604 | 521 | 4,969 |
Payments to suppliers and employees (AUD K) | — | -11,445 | -12,771 | -8,770 | -6,731 |
RDTI rebate received (AUD K) | — | 3,731 | 2,869 | 2,976 | 3,050 |
Operating cash flow (AUD K) | — | 703 | -4,303 | -5,471 | 1,019 |
Capital expenditure (AUD K) | — | 119 | 276 | 5 | 0 |
Free cash flow (AUD K, computed) | — | 584 | -4,579 | -5,476 | 1,019 |
Net equity raised (AUD K) | — | 0 | 0 | 3,376 | 868 |
Net short-term borrowings (AUD K) | — | 0 | 1,487 | 235 | -777 |
Lease principal repayments (AUD K) | — | -183 | -195 | -217 | -269 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD K) | — | 401 | -3,287 | -2,082 | 842 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ROE (%, net loss / average equity) | -8.6 | -96.9 | -276.6 | -48.5 |
ROA (%, net loss / average total assets) | -5.8 | -52.1 | -73.4 | -9.2 |
ROIC (%, EBIT / invested capital net of cash) | -0.2 | -133.6 | -148.5 | -8.2 |
Current ratio (x) | 4.14 | 1.61 | 1.07 | 1.37 |
Debt to equity excl. leases (x) | 0.00 | 0.45 | 1.69 | 0.65 |
Debt to equity incl. leases (x) | 0.27 | 1.13 | 3.55 | 1.72 |
Net debt incl. leases to EBITDA (x) | -6.64 | — | — | 3.24 |
Interest coverage EBIT / interest (x) | -0.05 | -30.11 | -18.59 | -0.66 |
Asset turnover (x, revenue / average assets) | 0.90 | 0.73 | 0.56 | 1.01 |
Days sales outstanding, customer receivables (days) | 17 | 0 | 221 | 30 |
Revenue by Region
| Region (AUD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Australia (AUD K) | — | — | — | 3,338 | 3,648 |
United States (AUD K) | — | — | — | 1,190 | 2,948 |
Europe and other countries (AUD K) | — | — | — | 0 | 0 |
Total (AUD K) | 5,103 | 11,928 | 8,098 | 4,528 | 6,596 |
Region growth | FY2026 vs FY2025 | — | — | — | — |
Australia | +9.3% (AUD 3,338k to AUD 3,648k): RDTI fell AUD 1,361k but was more than offset by the AUD 1,350k Richter milestone and AUD 346k fee-for-service income | — | — | — | — |
United States | +147.7% (AUD 1,190k to AUD 2,948k): full-year Nitroglycerin and Dapsone 7.5% profit share plus AUD 829k divestment proceeds; approximately +78% excluding divestment | — | — | — | — |
Europe and other | Nil in both years following the January 2023 sale of Lenzetto royalties; the Saudi Arabian Dapsone licence (July 2025) generated no disclosed revenue | — | — | — | — |
Per-Share Data and Share Count (millions)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|
Share price at 30 June (AUD cents) | 14.5 | 13.0 | 5.2 | 4.2 | 7.0 | 1.6 | 1.2 |
Shares on issue (millions) | 168.58 | 283.31 | 285.36 | 288.18 | 290.72 | 407.76 | 522.78 |
Market capitalisation (AUD Mn) | 24.44 | 36.83 | 14.84 | 12.10 | 20.35 | 6.93 | 6.27 |
Valuation Multiples
| Multiple | Acrux | Comment |
|---|---|---|
EV/EBITDA | ~29x | On computed FY26 EBITDA of AUD 0.25m; not meaningful given one-off income |
EV/Sales (total revenue) | ~1.1x | On FY26 revenue of AUD 6.6m (includes RDTI) |
EV/Sales (product-agreement revenue) | ~1.6x | On FY26 AUD 4.64m |
P/B | ~4.4x | On FY26 equity of AUD 1.47m |
Capital Instruments
| Instrument | Number | Exercise price | Expiry |
|---|---|---|---|
ACRO listed options | 160,472,177 | 5.25c | 19 Feb 2027 |
Placement attaching options | Up to 84,210,520 | 1.8c | ~July 2029 |
Lead-manager options (Alpine Capital) | 26,228,068 | 1.8c | ~July 2029 |
CEO options | 8,000,000 | 2.31c (Tranche 1; later tranches ≥ that) | December 2032 |
Rights held by directors and employees | 16,265,181 | Various (nil to 7.9c hurdle) | 2030–2032 |
Loan-funded ESOP shares approved (CEO and NEDs) | Up to 15,750,000 | Interest-free limited-recourse loan | — |
Analyst Conclusions
Management guidance. Management offers no numeric guidance. Its stated FY27 priorities (FY26 Chair and CEO report) are to progress partnership discussions, finalise the proposed Phase III programme, and advance manufacturing and regulatory activities, while applying "disciplined capital management." It expects material FY27 savings from headcount reduction and overhead rationalisation, receipt of the FY26 RDTI (~AUD 1.98m, of which AUD 0.95m will repay Radium), and potential receipt of up to AUD 4.05m in Lenzetto Australia milestones contingent on TGA approval and sales. The directors' liquidity assessment is that cash plus planned initiatives fund operations for at least 15 months from 30 June 2026.
Consensus growth expectations. None available; the stock is effectively uncovered.
Bull case
-
A partnership could re-rate the company several-fold. With an enterprise value of roughly AUD 7m, even a modest upfront payment from a co-development partner for a first-in-class FDA-approvable female testosterone product would be large relative to the market capitalisation; the company reports shortlisted parties are already in data-room due diligence (FY26 Annual Report).
-
De-risked science and regulatory pathway. A completed Phase II with a statistically significant primary endpoint at the 90 µL dose, FDA feedback indicating a viable Phase III path (April 2026), a potential 505(b)(2) route, and a TGA literature-based pathway together lower the development burden relative to a new chemical entity.
-
Self-funding base improving. FY26 delivered positive operating cash flow of AUD 1.02m, US profit share rose ~78% underlying, operating costs are falling, and up to AUD 4.05m of Lenzetto milestones provide non-dilutive upside — together reducing the need for deeply discounted equity.
Bear case
-
The FY26 "turnaround" was manufactured by one-offs. Excluding the AUD 1.35m Richter signing fee and AUD 0.83m ANDA sale, FY26 pre-tax loss would have been about AUD 2.65m; RDTI is shrinking (AUD 3.30m to AUD 1.94m), and the generic income base is exposed to the very price erosion that prompted two divestments.
-
Partnering is uncertain and the category has a poor record. No deal has been announced five months after a placement explicitly intended to support one; female testosterone has a history of regulatory and commercial failure (Intrinsa, LibiGel), and approved HSDD drugs have under-delivered commercially relative to large addressable-market claims like Acrux's US$21.3bn estimate.
-
Dilution and governance overhangs. The share count has roughly doubled since mid-2024 to ~588m, with over 300m options and rights outstanding, financing at 16% interest, and a going-concern material uncertainty; a weak-negotiating-position partnership could transfer most of the asset's value to the partner.
Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable | Why it matters |
|---|---|---|
| Q4 CY2026 | Announcement (or absence) of a Female Testosterone co-development agreement — upfront, milestones, cost-sharing, territory | Single most important value driver; determines funding of Phase III |
| Q4 CY2026 | Formalised FDA pre-IND feedback; Phase III design (size, duration, safety requirements) | Defines cost and timeline; safety-data requirements are a key risk |
| Oct 2026 / Jan 2027 / Apr 2027 | Quarterly Appendix 4C cash reports | Tracks burn, receipts, RDTI timing |
| Q2 FY2027 | Receipt of FY26 RDTI and repayment of Radium advance | Liquidity |
| Nov 2026 | AGM — remuneration, director re-elections, any capital-management resolutions | Governance; shareholder sentiment |
| FY2027 | TGA registration of Lenzetto by Gedeon Richter (triggers regulatory milestone) | Up to AUD 4.05m additional non-dilutive income across milestones |
| FY2027 | Execution of headcount and lease rationalisation | Cash-burn reduction; retention of key know-how |
| 19 Feb 2027 | Expiry of 160.5m ACRO options at 5.25c (deep out of the money) | Removes overhang; no funding expected from exercise |
| Feb 2027 | Half-year results (Appendix 4D), aggregator-listed for late Feb/early Mar 2027 | First read on underlying profitability without FY26 one-offs |
| Ongoing | US profit-share trends for Nitroglycerin and Dapsone; any further ANDA divestments | Income-base durability |
Analyst verdict
Acrux has completed one of the more consequential strategic pivots among ASX micro-cap life-science companies: from a sub-scale US topical generics developer, which by management's own admission was being squeezed by crowded, price-competitive markets, to a single-asset women's-health play centred on a Female Testosterone Metered Dose Transdermal System for HSDD. The logic is sound. Acrux's genuine edge has always been its metered-dose transdermal spray know-how, proven by Evamist, Axiron and a Lenzetto franchise that still sells around EUR 50 million a year for Gedeon Richter. The female testosterone programme has completed Phase II with a statistically significant primary endpoint, the regulatory environment for hormone therapy in women is more receptive than at any time since the programme began, and no FDA-approved female testosterone exists.
The financial reality, however, is fragile. FY2026's near-breakeven result rested on AUD 2.2 million of non-recurring income; cash is AUD 1.7 million, equity AUD 1.5 million, financing is short-term at 16%, and the auditors' going-concern disclosure remains. The company cannot fund Phase III and cannot borrow long-term; its strategy therefore reduces to a single question — can it sign a credible co-development partner on terms that leave meaningful economics with shareholders? Its bargaining position is weak, its share price sits below the strike of recently issued options, and the share count has doubled in two years.
On balance, Acrux should be viewed as a high-risk, binary, event-driven option on partnering success rather than an operating business to be valued on earnings. A well-structured deal with an established women's-health company could justify a valuation several times the current AUD 6–7 million capitalisation; failure to secure one within the next two to three quarters would likely force further deeply dilutive capital raising or asset monetisation. The next 12 months — partner announcement, FDA Phase III requirements and Lenzetto TGA approval — will decide which outcome prevails. Investors should size positions accordingly and treat management's US$21.3 billion market estimate as aspirational.
End of dossier. All figures AUD unless stated; FY ends 30 June. Derived metrics are computed from filed line items.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education | FY26 total remuneration (AUD) |
|---|---|---|---|---|---|
John Warmbrunn | CEO and Managing Director (Executive Director) | Since 1 June 2025 | 12 years in senior commercial roles at Ego Pharmaceuticals (grew export business to over 50% of turnover); Sandoz/Novartis (established OTC business in Australia and New Zealand); Bristol Myers Squibb (ConvaTec); CEO of Bendigo Community Telco (NSX: BCT), led IPO | BSc (Genetics), University of Melbourne; MBA, Macquarie Business School; MAICD | 492,828 (salary 375,000; STI accrual 33,750; super 30,000; options 33,506; leave movements 20,572) |
Joanna Johnson | CFO and Company Secretary | Company Secretary since June 2021 | CFO/Company Secretary IDT Australia and Generic Health; Finance Director Asia Pacific, Hospira and Mayne Pharma; FH Faulding | CA; BEc (Adelaide); Grad Dip Business Management (UniSA) | 318,411 |
Felicia Colagrande | Product Development and Technical Affairs Director | Director role since February 2015; joined Acrux 2001 | Faulding Pharmaceuticals; Austin Hospital Clinical Pharmacology; Silliker-Microtech; Adjunct Lecturer, Monash Pharmacy | BSc (Hons), La Trobe; MBA, Australian Institute of Business | 301,354 |
Mark Hyman | Project and Technical Development Director | Since July 2020 | 30+ years in quality, manufacturing, operations, product development and project management across prescription and consumer health | BSc (Chemistry and Pharmacology), Monash | 298,873 |
Dr Jolanta Airey | Chief Medical Officer | Appointed 24 August 2026 | CMO, Cynata Therapeutics (2021–2026); previously Medical Monitor on Acrux's testosterone formulation that led to Axiron's launch | MD (further details not publicly disclosed) | Not yet disclosed |
Board of Directors
| Name | Role | Appointed | Independence | Committees | Background | FY26 remuneration (AUD) |
|---|---|---|---|---|---|---|
Ross Dobinson | Chairman | March 1998 (Chair since January 2006; Executive Chair July 2012 – October 2014) | Classified by the company as independent, although he is a founder and former CEO | Attends committees by invitation | Investment banking and stockbroking; founding director of Starpharma; former director of Reliance Worldwide, Hexima, TPI Enterprises/Palla Pharma, Roc Oil, Racing Victoria | 129,319 |
Dr Geoff Brooke | Non-executive Director | June 2016 | Independent | Audit and Risk; Human Capital and Nomination | Co-founder GBS Venture Partners (1996); founder of Medvest with Johnson & Johnson; Chair of Actinogen Medical and Cynata Therapeutics; director of Saluda Medical | 83,577 |
Don Brumley | Non-executive Director | June 2021 | Independent | Chair, Audit and Risk; member, Human Capital and Nomination | 30 years as senior partner at Ernst & Young Oceania (Oceania IPO Leader, Biotech Markets Leader); former Chair of Bio-Gene Technology | 83,577 |
Dr Tim Oldham | Non-executive Director | October 2013 | Independent | Chair, Human Capital and Nomination; member, Audit and Risk | CEO and MD of AdAlta (ASX: 1AD); former President Asia Pacific, Hospira; Mayne Pharma; McKinsey | 83,577 |
John Warmbrunn | CEO and Managing Director | 1 June 2025 | Executive | — | See above | 492,828 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
7 February 2025 | CEO Michael Kotsanis announces retirement after more than 10 years | Chair credited him with implementing the generic strategy and six FDA approvals in four years |
30 May 2025 | Kotsanis ceases as CEO and KMP; remains employee to 4 July 2025 for transition; 4.5m unvested performance rights cancelled | FY26 Annual Report |
1 June 2025 | John Warmbrunn commences as CEO and MD | Commercially oriented hire from Ego Pharmaceuticals; mandate to expand international presence |
24 August 2026 | Dr Jolanta Airey appointed Chief Medical Officer | To lead Phase III design and execution for Female Testosterone |
Major Shareholders
| Holder | Ordinary shares | ACRO listed options | Unvested/unexercised rights or options |
|---|---|---|---|
Ross Dobinson | 10,746,351 | 571,428 | 2,257,130 rights |
Don Brumley | 8,809,060 | 2,285,714 | 1,433,359 rights |
Tim Oldham (incl. related entities) | 5,198,307 | 285,714 | 1,433,359 rights |
Geoff Brooke (incl. related entities) | 1,976,015 | 285,714 | 4,826,333 rights |
Felicia Colagrande | 770,415 | 285,714 | 1,015,000 rights |
Mark Hyman | 66,477 | 0 | 1,015,000 rights |
Joanna Johnson | 0 | 0 | 1,015,000 rights |
John Warmbrunn | 0 | 0 | 8,000,000 options |
Total KMP | 27,566,625 (≈5.3% of 522.8m shares) | 3,714,284 | — |
Competitive Landscape
Market Share by Competitor
| Competitor | Arena | Relevant products / position | Comparative revenue / share |
|---|---|---|---|
Taro Pharmaceutical (Sun Pharma) | Topical generics | Leading US topical/dermatology generics player | — |
Glenmark Pharmaceuticals | Topical generics | Large US dermatology generics portfolio | — |
Teva Pharmaceuticals | Topical generics / women's health | Broad generic portfolio including topicals and hormone products | — |
Viatris | Topical generics | Generic topicals and hormone products | — |
Zydus Lifesciences | Topical generics | Growing US topical generics including complex semi-solids | — |
Padagis | Topical generics (also an Acrux partner) | Specialist US topical generics; markets Evamist | — |
Encube Ethicals | Topical generics (CDMO / developer) | Indian topical semi-solid developer and manufacturer | — |
Sprout Pharmaceuticals | HSDD | Addyi (flibanserin), FDA-approved oral therapy for premenopausal HSDD | — |
Cosette Pharmaceuticals | HSDD | — | — |
Lawley Pharmaceuticals | Female testosterone (Australia) | — | — |
Off-label male testosterone gels and compounded products | Female testosterone | The de facto standard of care: Acrux notes women are frequently prescribed male products, creating dosing and transfer issues | Not quantified |
Gedeon Richter (also partner) | Women's health / MHT | Lenzetto (Acrux-developed); broad women's-health portfolio — potential competitor or partner | Lenzetto sales ~EUR 50m (2025), per Acrux |
Competitor Detail
| Metric | Acrux (FY2026) |
|---|---|
Revenue | AUD 6.6m |
Revenue growth | +45.7% (one-off assisted) |
Net margin | –9.2% |
EBITDA margin | +3.8% (computed) |
R&D intensity (external R&D / revenue) | 15.8% (understated; excludes in-house scientists) |
Business model | Out-licensing / profit share |



